# Medirom Healthcare Technologies Inc.: Form 20-F for the period ended Dec 31, 2024

- Company: [Medirom Healthcare Technologies Inc.](/companies/mrm.md) (CIK 1819704)
- Form: 20-F
- Filed: 2025-04-29
- Accepted by EDGAR: Apr 29, 2025, 20:15 ET
- Period: 2024-12-31
- Accession: 0001558370-25-005850
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1819704/000155837025005850/mrm-20241231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1819704/000155837025005850/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2024-01-01 to 2024-12-31 | JPY 8.30bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months, 2024-01-01 to 2024-12-31 | JPY 6.05bn | us-gaap:CostOfRevenue |
| Gross profit | 12 months, 2024-01-01 to 2024-12-31 | JPY 2.25bn | us-gaap:GrossProfit |
| Selling, general and administrative | 12 months, 2024-01-01 to 2024-12-31 | JPY 2.24bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2024-01-01 to 2024-12-31 | −JPY 18.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2024-01-01 to 2024-12-31 | JPY 49.7m | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months, 2024-01-01 to 2024-12-31 | −JPY 90.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2024-01-01 to 2024-12-31 | JPY 148.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2024-01-01 to 2024-12-31 | JPY 28.52 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2024-01-01 to 2024-12-31 | JPY 29.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2024-01-01 to 2024-12-31 | 5,851,516 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2024-01-01 to 2024-12-31 | −JPY 1.33bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2024-01-01 to 2024-12-31 | JPY 71.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-12-31 | $2.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-12-31 | JPY 2.71bn | us-gaap:AssetsCurrent |
| Total assets | at 2024-12-31 | JPY 8.09bn | us-gaap:Assets |
| Current liabilities | at 2024-12-31 | JPY 4.18bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-12-31 | JPY 6.90bn | us-gaap:Liabilities |
| Long-term debt | at 2024-12-31 | JPY 764.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-12-31 | JPY 620.8m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2024-12-31 | JPY 491.7m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2024-12-31 | JPY 933.3m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2024-12-31 | 7,901,950 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1819704/000155837025005850/mrm-20241231x20f.htm

Filed Apr 29, 2025.
Source: SEC EDGAR, the filing index for accession 0001558370-25-005850. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.